tempest therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways. tempest has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct immune response pathways relevant to mounting an effective anti-tumor response. the molecules were developed by inception sciences, a versant ventures affiliated drug discovery engine. tempest has assembled a highly experienced team of small molecule and immuno-oncology drug developers to advance these programs to the clinic across diverse cancers representing significant unmet medical need. tempest is backed by a syndicate of leading us and china based venture capital firms.
Company profile
Ticker
TPST
Exchange
Website
CEO
Julia Owens
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Millendo Therapeutics, Inc., OvaScience, Inc.
SEC CIK
Corporate docs
Subsidiaries
TempestTx, Inc. • Millendo Therapeutics US, Inc. ...
IRS number
451472564
TPST stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
S-8
Registration of securities for employees
19 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Tempest Reports Year End 2023 Financial Results and Provides Business Update
19 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
17 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
17 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
17 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
17 Nov 23
Latest ownership filings
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
Rock Springs Capital Management LP
14 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13D/A
Versant Venture Capital VI, L.P.
8 Feb 24
4
Stephen R Brady
5 Jan 24
4
Samuel Whiting
5 Jan 24
4
Justin Trojanowski
5 Jan 24
4
Nicholas Maestas
5 Jan 24
SC 13D/A
Versant Venture Capital VI, L.P.
9 Nov 23
144
Notice of proposed sale of securities
2 Nov 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 11.51 mm | 11.51 mm | 11.51 mm | 11.51 mm | 11.51 mm | 11.51 mm |
Cash burn (monthly) | 2.16 mm | 2.64 mm | 2.20 mm | 2.55 mm | 2.16 mm | 2.31 mm |
Cash used (since last report) | 14.87 mm | 18.20 mm | 15.16 mm | 17.58 mm | 14.92 mm | 15.91 mm |
Cash remaining | -3.37 mm | -6.70 mm | -3.66 mm | -6.08 mm | -3.42 mm | -4.40 mm |
Runway (months of cash) | -1.6 | -2.5 | -1.7 | -2.4 | -1.6 | -1.9 |
Institutional ownership, Q2 2023
27.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 25 |
Opened positions | 8 |
Closed positions | 2 |
Increased positions | 6 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 4.74 bn |
Total shares | 6.17 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Versant Venture Capital VI | 2.12 mm | $7.65 mm |
EcoR1 Capital | 1.12 mm | $1.43 bn |
FMR | 647.90 k | $822.83 mm |
Rock Springs Capital Management | 536.21 k | $680.99 mm |
AIGH Capital Management | 406.25 k | $515.94 mm |
Vanguard | 309.84 k | $393.50 mm |
Sectoral Asset Management | 219.39 k | $278.63 mm |
LAV Regulus | 153.74 k | $812.00 k |
FIL | 129.58 k | $164.57 mm |
Renaissance Technologies | 103.40 k | $131.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Jan 24 | Nicholas Maestas | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.66 | 40,000 | 186.40 k | 40,000 |
3 Jan 24 | Justin Trojanowski | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.66 | 26,500 | 123.49 k | 26,500 |
3 Jan 24 | Samuel Whiting | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.66 | 100,000 | 466.00 k | 100,000 |
3 Jan 24 | Stephen R Brady | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.66 | 250,000 | 1.17 mm | 250,000 |
11 Oct 23 | Samuel Whiting | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 9.77 | 325,000 | 3.18 mm | 325,000 |
News
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
5 Apr 24
Tempest Announces Publication Of Data From Phase 1 Trial Of TPST-1120 In Patients With Advanced Solid Tumors In Journal Of Cancer Research Communications
4 Apr 24
Tempest FY23 EPS $(1.91) Vs $(3.09) YoY; Ended The Year With $39.2M In Cash And Cash Equivalents
19 Mar 24
Scotiabank Initiates Coverage On Tempest Therapeutics with Sector Outperform Rating, Announces Price Target of $13
14 Mar 24
HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Maintains $47 Price Target
12 Mar 24
Press releases
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
14 Mar 24
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2 Feb 24
Thinking about buying stock in Agape ATP, Tempest Therapeutics, Nu Holdings, Bristol-Myers Squibb, or Petros Pharmaceuticals?
30 Jan 24
Tempest Therapeutics Announces Groundbreaking Advances in Liver Cancer Treatment, Showcasing Exceptional Efficacy and Safety Data at ASCO Annual Meeting 2024
30 Jan 24